MarginsXMarginsX
Home › Markets › Health Care › NCEL

NewcelX Ltd. (NCEL)

NCEL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.75
+5.36% on the day
Market cap
$15.9M
Nano cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerNCEL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySwitzerland
IPO year2021
SEC CIK0001783036
SEC industry codePharmaceutical Preparations
Incorporated inSwitzerland

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
9.5 months
$2.2M cash at December 31, 2025
Share count, 1 year
+1418.4%
2024-12-31 to 2025-12-31 · +5817.6% over 3 years
Going-concern doubt
Yes
20-F filed April 29, 2026
Insider net buying, 12 months
$375K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements."
20-F 2026-04-29
Cash and burn$2.2M cash; operating cash flow -$692K a quarter.Report 2025-12-31
Shares outstanding4,797,505 (2025-12-31); 3,159,535 a year earlier; 32,428,893 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-400 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years2; latest 1-for-10 on 2025-10-31Source 2025-10-31
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-08-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE/A filed25-NSE/A 2025-10-30
AuditorKost Forer Gabbay & Kasierer, Tel Aviv, IsraelPCAOB Form AP 2026-05-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $375K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$8.3M-$2.8M$2.2M$355KNeeds four quarters20-F 2026-04-29
FY 2024
2024-12-31
Not filed-$7.2M-$1.1M$650K$7.7MNeeds four quarters20-F 2026-04-29
FY 2023
2023-12-31
Not filed-$3.3M-$3.4M$1.1MNo debt tagsNeeds four quarters20-F 2026-04-29
FY 2022
2022-12-31
Not filed-$16.5M-$13.9M$8.9MNo debt tagsNeeds four quarters20-F 2025-05-16
FY 2021
2021-12-31
Not filed-$11.9M-$14.9M$5.4MNo debt tagsNeeds four quarters20-F 2024-05-15
FY 2020
2020-12-31
Not filed-$2.9M-$729K$94K$113KNeeds four quarters20-F 2023-05-05
FY 2019
2019-12-31
Not filed-$5.4M-$190K$220K$692KNeeds four quarters20-F 2022-03-24
FY 2018
2018-12-31
Not filed-$5.1M-$2.7M$7KNo debt tagsNeeds four quarters20-F 2021-05-14

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1
POS AM2026-09-18
Latest annual report
ANNUAL REPORT
20-F2026-04-29
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-09

Source: SEC EDGAR submissions feed, 419 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.2%
1 month-8.1%
3 months-27.5%
Year to date+37.4%
1 year-23.9%
From 52-week high-46.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CNTXContext Therapeutics Inc.$0.1659-8.24%$15.2M
AKTXAkari Therapeutics plc ADS$6.51-4.26%$15.1M
BOLTBolt Biotherapeutics Inc.$5.80-4.61%$15.1M
KTTAPasithea Therapeutics Corp.$0.5000-4.21%$16.7M
PBMPsyence Biomedical Ltd. Common Shares$2.83-11.56%$15.0M
QNRXQuoin Pharmaceuticals Ltd.$3.56-3.78%$17.1M
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier